PURPOSE: To evaluate the effect of the intravenous (i.v.) L-alanyl-L-glutamine dipeptide supplementation during 5 days on clinical outcome in trauma patients admitted to the intensive care unit (ICU). METHODS: This was a prospective, randomized, double-blind, multicenter trial. Glutamine was not given as a component of nutrition but as an extra infusion. The primary outcome variable was the number of new infections within the first 14 days. RESULTS: We included 142 patients. There were no differences between groups in baseline characteristics. Up to 62 % of the patients in the placebo group and 63 % in the treatment group presented confirmed infections (p = 0.86). ICU length of stay was 14 days in both groups (p = 0.54). Hospital length of stay was 27 days in the placebo group and 29 in the treatment group (p = 0.88). ICU mortality was 4.2 % in both groups (p = 1). Sixty percent of the patients presented low glutamine levels before randomization. At the end of the treatment (6th day), 48 % of the patients maintained low glutamine levels (39 % of treated patients vs. 57 % in the placebo group). Patients with low glutamine levels at day 6 had more number of infections (58.8 vs. 80.9 %; p = 0.032) and longer ICU (9 vs. 20 days; p < 0.01) and hospital length of stay (24 vs. 41 days; p = 0.01). CONCLUSIONS: There was no benefit with i.v. L-alanyl-L-glutamine dipeptide supplementation (0.5 g/kg body weight/day of the dipeptide) during 5 days in trauma patients admitted to the ICU. The i.v. glutamine supplementation was not enough to normalize the plasma glutamine levels in all patients. Low plasma glutamine levels at day 6 were associated with a worse outcome.
RCT Entities:
PURPOSE: To evaluate the effect of the intravenous (i.v.) L-alanyl-L-glutamine dipeptide supplementation during 5 days on clinical outcome in traumapatients admitted to the intensive care unit (ICU). METHODS: This was a prospective, randomized, double-blind, multicenter trial. Glutamine was not given as a component of nutrition but as an extra infusion. The primary outcome variable was the number of new infections within the first 14 days. RESULTS: We included 142 patients. There were no differences between groups in baseline characteristics. Up to 62 % of the patients in the placebo group and 63 % in the treatment group presented confirmed infections (p = 0.86). ICU length of stay was 14 days in both groups (p = 0.54). Hospital length of stay was 27 days in the placebo group and 29 in the treatment group (p = 0.88). ICU mortality was 4.2 % in both groups (p = 1). Sixty percent of the patients presented low glutamine levels before randomization. At the end of the treatment (6th day), 48 % of the patients maintained low glutamine levels (39 % of treated patients vs. 57 % in the placebo group). Patients with low glutamine levels at day 6 had more number of infections (58.8 vs. 80.9 %; p = 0.032) and longer ICU (9 vs. 20 days; p < 0.01) and hospital length of stay (24 vs. 41 days; p = 0.01). CONCLUSIONS: There was no benefit with i.v. L-alanyl-L-glutamine dipeptide supplementation (0.5 g/kg body weight/day of the dipeptide) during 5 days in traumapatients admitted to the ICU. The i.v. glutamine supplementation was not enough to normalize the plasma glutamine levels in all patients. Low plasma glutamine levels at day 6 were associated with a worse outcome.
Authors: Margaret McQuiggan; Rosemary Kozar; R Matthew Sailors; Chul Ahn; Bruce McKinley; Frederick Moore Journal: JPEN J Parenter Enteral Nutr Date: 2008 Jan-Feb Impact factor: 4.016
Authors: Christiane Goeters; Anke Wenn; Norbert Mertes; Carola Wempe; Hugo Van Aken; Peter Stehle; Hans-Georg Bone Journal: Crit Care Med Date: 2002-09 Impact factor: 7.598
Authors: Pierre Singer; Mette M Berger; Greet Van den Berghe; Gianni Biolo; Philip Calder; Alastair Forbes; Richard Griffiths; Georg Kreyman; Xavier Leverve; Claude Pichard Journal: Clin Nutr Date: 2009-06-07 Impact factor: 7.324
Authors: Peter J D Andrews; Alison Avenell; David W Noble; Marion K Campbell; Bernard L Croal; William G Simpson; Luke D Vale; Claire G Battison; David J Jenkinson; Jonathan A Cook Journal: BMJ Date: 2011-03-17
Authors: Jon Pérez-Bárcena; Abelardo García-de-Lorenzo; Antonio Buño; Juan A Llompart-Pou Journal: Intensive Care Med Date: 2014-08-06 Impact factor: 17.440
Authors: J M Raurich; J A Llompart-Pou; A García-de-Lorenzo; A Buño Soto; P Marsé; G Frontera; J Pérez-Bárcena Journal: Eur J Trauma Emerg Surg Date: 2017-10-04 Impact factor: 3.693
Authors: Luis Servia; José C E Serrano; Reinald Pamplona; Mariona Badia; Neus Montserrat; Manuel Portero-Otin; Javier Trujillano Journal: PLoS One Date: 2018-10-11 Impact factor: 3.240